Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Galactomannan C

Drug Profile

Galactomannan C

Alternative Names: Carbohydrate polymer; DAVANAT®; GM-CT-01

Latest Information Update: 22 Mar 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Pro-Pharmaceuticals
  • Developer Galectin Therapeutics; Icahn School of Medicine at Mount Sinai; Pro-Pharmaceuticals
  • Class Antineoplastics; Mannans; Polymers
  • Mechanism of Action Galectin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes - Colorectal cancer

Highest Development Phases

  • Discontinued Biliary cancer; Breast cancer; Colorectal cancer; Hepatic fibrosis; Malignant melanoma

Most Recent Events

  • 22 Mar 2019 Discontinued - Phase-I/II for Malignant melanoma (Combination therapy, Metastatic disease) in Belgium (IV)
  • 12 Mar 2019 Cliniques universitaires Saint-Luc- Université Catholique de Louvain terminates a phase I/II trial in Malignant melanoma (Combination therapy, Metastatic disease) in Belgium (NCT01723813)
  • 24 Jun 2018 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top